Skip to main content
Log in

Structural genomics in the biotechnology sector

  • Perspective
  • Published:

From Nature Structural Biology

View current issue Submit your manuscript

Abstract

Commercial efforts in structural genomics focus on providing to pharmaceutical customers information that relates to the suitability of specific proteins as drug targets and the informed selection and refinement of lead compounds generated by high-throughput screening and rational approaches. These efforts follow a variety of business models and are impacted by activities in the public domain, recent technological advances, and the changing intellectual property landscape.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: Potential impact of structural genomics on drug discovery.

Similar content being viewed by others

References

  1. Boggon, T.J., Shan, W.S., Santagata, S., Myers, S.C. & Shapiro, L. Science, 286, 2119–2125 (1999).

    Article  CAS  Google Scholar 

  2. Shapiro, L. & Scherer, P.W. Curr. Biol. 8, 335–338 (1998).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dry, S., McCarthy, S. & Harris, T. Structural genomics in the biotechnology sector. Nat Struct Mol Biol 7 (Suppl 11), 946–949 (2000). https://doi.org/10.1038/80718

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/80718

  • Springer Nature America, Inc.

This article is cited by

Navigation